(-1.57%) 5 035.69 points
(-1.49%) 37 816 points
(-2.04%) 15 658 points
(-0.73%) $81.33
(-1.66%) $1.958
(-0.04%) $2 302.00
(-0.17%) $26.61
(-0.27%) $945.60
(0.06%) $0.938
(0.21%) $11.12
(0.05%) $0.801
(0.00%) $93.45
Live Chart Being Loaded With Signals
The United Laboratories International Holdings Limited, an investment holding company, engages in the research, development, manufacture, distribution, and sale of pharmaceutical products...
Stats | |
---|---|
Šios dienos apimtis | 2.85M |
Vidutinė apimtis | 4.02M |
Rinkos kapitalizacija | 16.77B |
EPS | HKD0 ( 2024-03-26 ) |
Last Dividend | HKD0.131 ( 2023-09-14 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 5.63 |
ATR14 | HKD0.00700 (0.08%) |
Tūris Koreliacija
United Laboratories Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
United Laboratories Koreliacija - Valiuta/Žaliavos
United Laboratories Finansinės ataskaitos
Annual | 2023 |
Pajamos: | HKD13.74B |
Bruto pelnas: | HKD6.33B (46.11 %) |
EPS: | HKD1.490 |
FY | 2023 |
Pajamos: | HKD13.74B |
Bruto pelnas: | HKD6.33B (46.11 %) |
EPS: | HKD1.490 |
FY | 2022 |
Pajamos: | HKD11.33B |
Bruto pelnas: | HKD4.97B (43.84 %) |
EPS: | HKD0.870 |
FY | 2021 |
Pajamos: | HKD9.70B |
Bruto pelnas: | HKD4.21B (43.40 %) |
EPS: | HKD0.560 |
Financial Reports:
No articles found.
United Laboratories Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0.0801 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.196 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.156 | 2008-05-26 |
Last Dividend | HKD0.131 | 2023-09-14 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 15 | -- |
Total Paid Out | HKD1.398 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.66 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.52 | |
Div. Directional Score | 7.71 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
2883.HK | Ex Dividend Knight | 2023-06-07 | Annually | 0 | 0.00% | |
1480.HK | Ex Dividend Knight | 2023-06-08 | Sporadic | 0 | 0.00% | |
0551.HK | Ex Dividend Junior | 2023-09-12 | Annually | 0 | 0.00% | |
8053.HK | No Dividend Player | 2023-09-28 | Annually | 0 | 0.00% | |
2001.HK | Ex Dividend Knight | 2023-09-01 | Annually | 0 | 0.00% | |
1072.HK | Ex Dividend Junior | 2023-06-30 | Sporadic | 0 | 0.00% | |
0151.HK | Ex Dividend Knight | 2023-08-24 | Semi-Annually | 0 | 0.00% | |
3669.HK | Ex Dividend Junior | 2023-09-07 | Annually | 0 | 0.00% | |
1635.HK | Ex Dividend Junior | 2023-06-30 | Annually | 0 | 0.00% | |
0686.HK | Ex Dividend Junior | 2023-06-29 | Sporadic | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.197 | 1.500 | 6.07 | 9.10 | [0 - 0.5] |
returnOnAssetsTTM | 0.129 | 1.200 | 5.72 | 6.86 | [0 - 0.3] |
returnOnEquityTTM | 0.223 | 1.500 | 8.64 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 2.08 | 0.800 | 4.60 | 3.68 | [1 - 3] |
quickRatioTTM | 1.528 | 0.800 | 5.72 | 4.57 | [0.8 - 2.5] |
cashRatioTTM | 0.643 | 1.500 | 7.54 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0714 | -1.500 | 8.81 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.659 | 2.00 | 9.78 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.400 | 2.00 | 9.80 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.118 | -1.500 | 9.53 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.461 | 1.000 | 5.65 | 5.65 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.231 | 1.000 | 7.38 | 7.38 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.798 | 1.000 | 6.68 | 6.68 | [0.2 - 2] |
assetTurnoverTTM | 0.654 | 0.800 | 8.98 | 7.18 | [0.5 - 2] |
Total Score | 10.90 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 5.74 | 1.000 | 9.52 | 0 | [1 - 100] |
returnOnEquityTTM | 0.223 | 2.50 | 9.12 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.400 | 2.00 | 9.87 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.30 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.659 | 2.00 | 9.78 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.101 | 1.500 | -2.66 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0872 | 1.000 | -0.321 | 0 | [0.1 - 0.5] |
Total Score | 4.52 |
United Laboratories
The United Laboratories International Holdings Limited, an investment holding company, engages in the research, development, manufacture, distribution, and sale of pharmaceutical products. It operates through three segments: Bulk Medicine, Intermediate Products, and Finished Products. The company offers oral antibiotics, antimicrobials for injection, anti-cold products, cough medicines, ophthalmic drugs, antiviral drugs, anti-hepatitis B drugs, diabetes drugs, skin drugs for external use, cardiovascular and cerebrovascular drugs, nervous system drugs, vitamins, and vacant gelatin capsules, as well as API and intermediate products. It also manufactures and sells soft capsules casings; holds trademarks; and trades in pharmaceutical products. In addition, the company provides management services. It has operations in the People's Republic of China, Europe, India, the Middle East, South America, other Asian regions, and internationally. The company was founded in 1990 and is headquartered in Yuen Long, Hong Kong.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.